In 2019, a CAR-T directed against NKG2D (Natural Killer Group 2, Member D), a receptor that transmits activation signals in NK-cells and activates the immune system against NKG2D ligands, expressed in AML blasts and poorly expressed in healthy tissues [68], was tested in seven R/R AML patients. The gene discussed is KLRK1; the disease is acute myeloid leukemia.